ÂÜÀòÂÒÂ×

Michal Cabadaj, CAIA has a diverse work experience in the biotechnology and healthcare industry. Michal currently serves as the Senior Director of Business & Corporate Development at Mereo BioPharma since July 2022.

Prior to this role, Michal worked as a Guest Lecturer at the Cambridge University Department of Chemical Engineering and Biotechnology starting from January 2021.

From January 2019 to June 2022, Michal held the position of Senior Director of Business Development & Strategy at Wren Therapeutics Ltd.

Before joining Wren Therapeutics, Michal worked at Malin Corporation plc as a Venture Capital Investor from April 2016 to December 2018. Michal was responsible for sourcing, evaluating, and structuring new investments in private early-stage biotechnology companies, specializing in areas such as immunology, oncology, and gut microbiome.

Michal also has experience as an Equity Research Analyst in the healthcare and life sciences sector. Michal worked at Peel Hunt from February 2016 to March 2016, co-leading the coverage of small- and mid-cap healthcare companies. Prior to that, they served as an Equity Research Analyst at finnCap Ltd from October 2014 to February 2016, where they covered various UK-listed mid and small-cap biotech, pharmaceutical, and medical device companies.

Additionally, Michal had roles in business development and internships. Michal worked as a Business Development Associate at Saneca Pharma from February 2014 to October 2014, providing analytical support for generics business strategy. Michal also held internships at Sosei Heptares and IONTAS (Antibodies), where they gained experience in business development and commercialization strategies.

Overall, Michal Cabadaj, CAIA has extensive experience in business development, strategy, equity research, and venture capital investment within the biotechnology and healthcare sector.

Michal Cabadaj, CAIA, has a diverse educational background in the fields of Bioscience Enterprise, Management of Technology & Innovation, Finance and Investment, and International Accounting & Finance. In 2008, they began their undergraduate studies at Fachhochschule Wiener Neustadt, where they obtained a Bachelor of Arts (B.A.) degree with distinction in International Accounting & Finance in 2011.

After completing their bachelor's degree, Michal pursued a Master of Science (M.Sc.) in Finance and Investment at The University of Edinburgh from 2011 to 2012. During this time, they gained in-depth knowledge in finance-related subjects.

Michal's educational journey continued as they attended Cambridge University Department of Chemical Engineering and Biotechnology in 2012-2013. Here, they pursued a Master of Philosophy (M.Phil.) degree in Bioscience Enterprise, focusing on the interplay between science and business in the biotechnology industry. Concurrently, Michal also completed the Entrepreneurship Development Programme at Cambridge Judge Business School, specializing in the Management of Technology & Innovation (MoTI).

In addition to their academic achievements, Michal Cabadaj holds two notable certifications. Michal obtained the Chartered Alternative Investment Analyst (CAIA) designation from the CAIA Association in May 2022. Furthermore, they successfully cleared Level I of the CFA Program offered by the CFA Institute in September 2013. These certifications demonstrate their dedication to professional growth and expertise in the finance and investment industry.